Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations

NCT02383927 is registered in ClinicalTrials.gov with Kura Oncology, Inc. as lead sponsor.

NCT NCT02383927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02383927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations
Lead sponsor
Kura Oncology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 13, 2015
Completion date
December 14, 2020
Enrollment
63 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

hras mutant tumor, other squamous cell carcinoma (scc) with hras mutant tumor, squamous cell carcinoma head and neck cancer (hnscc), thyroid cancer